Former Gov. Andrew M. Cuomo acknowledged that he had not run an effective race in the mayoral primary and asked for ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday. CEO Albert Bourla ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

President Trump threatened 250% tariffs on pharma; Pfizer CEO contacted Trump about most favored nation pricing; Ex-X CEO joins eMed.

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

Pfizer ( PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

Pfizer Q2 2025 earnings show 10% revenue growth, raised EPS guidance, strong R&D, and operational execution. Explore growth drivers and policy risks.

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...